Clincosm LogoSign in Get a demo

Constraint-Induced (CI) Movement Therapy for Progressive Multiple Sclerosis (MS)

Sponsor
National Multiple Sclerosis Society (Other)
Overall Status
Completed
CT.gov ID
NCT00695084
Collaborator
(none)
7
Enrollment
1
Location
1
Arm
13
Duration (Months)
0.5
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This trial will evaluate whether progressive multiple sclerosis associated with hemiparesis may benefit from Constraint-Induced Movement Therapy.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Constraint-Induced Movement Therapy
 Phase 1

Detailed Description

Constraint-Induced Movement Therapy was developed to treat stroke hemiparesis. Due to the similarity between multiple sclerosis and stroke in terms of chronic motor deficit, this trial will attempt to determine whether multiple sclerosis may benefit similarly from Constraint-Induced Movement Therapy.

Study Design

Study Type:
Interventional
Actual Enrollment :
7 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Constraint-Induced Movement Therapy Trial for Progressive Multiple Sclerosis
Study Start Date :
Mar 1, 2007
Actual Primary Completion Date :
Apr 1, 2008
Actual Study Completion Date :
Apr 1, 2008

Arms and Interventions

Arm Intervention/Treatment
Experimental: 1

Treatment with Constraint-Induced Movement Therapy

Behavioral: Constraint-Induced Movement Therapy
Intensive practice with the hemiparetic arm for 30 contact hours
Other Names:
  • CI Therapy

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Improvement on the Motor Activity Log [One year]

    Secondary Outcome Measures

    1. Improvement on the Wolf Motor Function Test [Pre to post-treatment]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    21 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Chronic upper extremity motor deficit due to multiple sclerosis
    Exclusion Criteria:
    • Relapse within 3 months of planned enrollment.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Alabama at Birmingham Birmingham Alabama United States 35249

    Sponsors and Collaborators

    • National Multiple Sclerosis Society

    Investigators

    • Principal Investigator: Victor W Mark, MD, University of Alabama at Birmingham

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00695084
    Other Study ID Numbers:
    • CIMSTrial
    • PP1395
    First Posted:
    Jun 11, 2008
    Last Update Posted:
    Jun 11, 2008
    Last Verified:
    Jun 1, 2008
    Keywords provided by , ,
    multiple sclerosis
    Additional relevant MeSH terms:
    Multiple Sclerosis
    Multiple Sclerosis, Chronic Progressive
    Sclerosis

    Study Results

    No Results Posted as of Jun 11, 2008